Key Takeaways
- • Rhenman Healthcare Equity L/S is a long-biased global healthcare hedge fund maintaining an average net long exposure of approximately 125%, positioning it to capture secular growth trends in pharmaceuticals, medical devices, biotechnology, and healthcare services.
- • The fund ranked #1 among 52 global equity hedge funds in the "Global Equity EUR" category according to Eurohedge's performance rankings, demonstrating competitive returns relative to peers.
- • Fund structure includes multiple share classes (RC1 SEK and RC1 EUR) with reported performance metrics showing cumulative returns of 800.02% (SEK) and 735.44% (EUR) across the fund's lifetime, though recent performance showed negative returns (-3.53% SEK, -2.77% EUR).
- • Active management philosophy combines fundamental analysis with tactical trading, supported by a world-renowned Scientific Advisory Board that informs stock selection and portfolio positioning decisions.
- • Rhenman & Partners has expanded its product offering beyond the flagship Healthcare Equity L/S strategy, introducing smaller-cap healthcare focused strategies to capture additional investment opportunities in the sector.
Summary
Rhenman Healthcare Equity L/S is a long-biased hedge fund managed by Rhenman & Partners Asset Management AB (Rhepa), which serves as portfolio manager under delegation from ONE Fund Management S.A. The fund pursues a fundamental investment approach focused on global healthcare equities, including pharmaceuticals, medical devices, biotechnology, and healthcare services. The strategy maintains a structural long bias, with average net long exposure around 125%, designed to capitalize on secular growth dynamics within the healthcare and biotech industries while retaining flexibility to execute tactical short positions and market hedges.
The fund's performance has demonstrated competitive positioning within the global hedge fund landscape. According to Eurohedge's rankings, Rhenman Healthcare Equity L/S achieved the #1 position among 52 global hedge funds in the "Global Equity EUR" category, reflecting strong risk-adjusted returns relative to institutional peer benchmarks. The fund offers share classes in both SEK and EUR currencies, with cumulative lifetime returns of 800.02% (RC1 SEK) and 735.44% (RC1 EUR). However, more recent performance has turned negative, with the fund declining 3.53% in SEK and 2.77% in EUR, reflecting broader equity market headwinds in early 2022.
The fund's investment process leverages a world-renowned Scientific Advisory Board, which provides deep sector expertise to inform fundamental analysis and stock selection. This combination of scientific rigor and active portfolio management enables the strategy to identify alpha opportunities across the healthcare complex while managing sector-specific and company-specific risks through both long and short positioning.
Rhenman & Partners has subsequently expanded its product capabilities beyond the flagship Healthcare Equity L/S strategy, introducing smaller-cap healthcare focused strategies to broaden the firm's investment mandate and capture additional growth opportunities in nascent and mid-market healthcare companies. The fund is restricted to professional investors under UCITS regulations and does not provide investment recommendations directly to individual investors; prospective institutional investors are advised to consult professional investment advisors and review relevant fund documentation including prospectuses and Key Information Documents (KID).
The fund's performance has demonstrated competitive positioning within the global hedge fund landscape. According to Eurohedge's rankings, Rhenman Healthcare Equity L/S achieved the #1 position among 52 global hedge funds in the "Global Equity EUR" category, reflecting strong risk-adjusted returns relative to institutional peer benchmarks. The fund offers share classes in both SEK and EUR currencies, with cumulative lifetime returns of 800.02% (RC1 SEK) and 735.44% (RC1 EUR). However, more recent performance has turned negative, with the fund declining 3.53% in SEK and 2.77% in EUR, reflecting broader equity market headwinds in early 2022.
The fund's investment process leverages a world-renowned Scientific Advisory Board, which provides deep sector expertise to inform fundamental analysis and stock selection. This combination of scientific rigor and active portfolio management enables the strategy to identify alpha opportunities across the healthcare complex while managing sector-specific and company-specific risks through both long and short positioning.
Rhenman & Partners has subsequently expanded its product capabilities beyond the flagship Healthcare Equity L/S strategy, introducing smaller-cap healthcare focused strategies to broaden the firm's investment mandate and capture additional growth opportunities in nascent and mid-market healthcare companies. The fund is restricted to professional investors under UCITS regulations and does not provide investment recommendations directly to individual investors; prospective institutional investors are advised to consult professional investment advisors and review relevant fund documentation including prospectuses and Key Information Documents (KID).
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.